CARsgen’s Satri-cel Receives Priority Review from China’s NMPA

An update from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) is now available.

CARsgen Therapeutics Holdings Ltd. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Priority Review to its product candidate, satricabtagene autoleucel (satri-cel), for treating Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy. This development positions CARsgen as a leader in the CAR T-cell therapy sector, potentially impacting its market presence and offering new hope for patients with these specific cancer types.

The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.

More about CARsgen Therapeutics Holdings Ltd.

CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company focused on developing innovative CAR T-cell therapies to address unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases. The company has established comprehensive capabilities for CAR T-cell research and development, including target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen aims to be a global leader in providing innovative and differentiated cell therapies.

Average Trading Volume: 4,293,441

Technical Sentiment Signal: Buy

Current Market Cap: HK$11.68B

For a thorough assessment of 2171 stock, go to TipRanks’ Stock Analysis page.